Lentivirus-Mediated α-Melanocyte-Stimulating Hormone Overexpression in the Hypothalamus Decreases Diet Induced Obesity in Mice

K. Eerola, W. Nordlund, S. Virtanen, A. M. Dickens, M. Mattila, S. T. Ruohonen, Streamson C. Chua, Jr., S. L. Wardlaw, M. Savontaus, E. Savontaus

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Melanocyte stimulating hormone (MSH) derived from the pro-hormone pro-opiomelanocortin (POMC) has potent effects on metabolism and feeding that lead to reduced body weight in the long-term. To determine the individual roles of POMC derived peptides and their sites of action, we created a method for the delivery of single MSH peptides using lentiviral vectors and studied the long-term anti-obesity effects of hypothalamic α-MSH overexpression in mice. An α-MSH lentivirus (LVi-α-MSH-EGFP) vector carrying the N'-terminal part of POMC and the α-MSH sequence was generated and shown to produce bioactive peptide in an in vitro melanin synthesis assay. Stereotaxis was used to deliver the LVi-α-MSH-EGFP or control LVi-EGFP vector to the arcuate nucleus (ARC) of the hypothalamus of male C57Bl/6N mice fed on a high-fat diet. The effects of 6-week-treatment on body weight, food intake, glucose tolerance and organ weights were determined. Additionally, a 14-day pairfeeding study was conducted to assess whether the weight decreasing effect of the LVi-α-MSH-EGFP treatment is dependent on decreased food intake. The 6-week LVi-α-MSH-EGFP treatment reduced weight gain (8.4 ± 0.4 g versus 12.3 ± 0.6 g; P < 0.05), which was statistically significant starting from 1 week after the injections. The weight of mesenteric fat was decreased and glucose tolerance was improved compared to LVi-EGFP treated mice. Food intake was decreased during the first week in the LVi-α-MSH-EGFP treated mice but subsequently increased to the level of LVi-EGFP treated mice. The LVi-EGFP injected control mice gained more weight even when pairfed to the level of food intake by LVi-α-MSH-EGFP treated mice. We demonstrate that gene transfer of α-MSH, a single peptide product of POMC, into the ARC of the hypothalamus, reduces obesity and improves glucose tolerance, and that factors other than decreased food intake also influence the weight decreasing effects of α-MSH overexpression in the ARC. Furthermore, viral MSH vectors delivered stereotaxically provide a novel tool for further exploration of chronic site-specific effects of POMC peptides.

Original languageEnglish (US)
Pages (from-to)1298-1307
Number of pages10
JournalJournal of Neuroendocrinology
Volume25
Issue number12
DOIs
StatePublished - Dec 2013

Fingerprint

Melanocyte-Stimulating Hormones
Lentivirus
Hypothalamus
Obesity
Diet
Pro-Opiomelanocortin
Eating
Arcuate Nucleus of Hypothalamus
Peptides
Weights and Measures
Body Weight
Glucose
Organ Size
Melanins
High Fat Diet

Keywords

  • α-MSH
  • Mice
  • Neuropeptides
  • Obesity
  • POMC

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems
  • Cellular and Molecular Neuroscience
  • Medicine(all)

Cite this

Eerola, K., Nordlund, W., Virtanen, S., Dickens, A. M., Mattila, M., Ruohonen, S. T., ... Savontaus, E. (2013). Lentivirus-Mediated α-Melanocyte-Stimulating Hormone Overexpression in the Hypothalamus Decreases Diet Induced Obesity in Mice. Journal of Neuroendocrinology, 25(12), 1298-1307. https://doi.org/10.1111/jne.12109

Lentivirus-Mediated α-Melanocyte-Stimulating Hormone Overexpression in the Hypothalamus Decreases Diet Induced Obesity in Mice. / Eerola, K.; Nordlund, W.; Virtanen, S.; Dickens, A. M.; Mattila, M.; Ruohonen, S. T.; Chua, Jr., Streamson C.; Wardlaw, S. L.; Savontaus, M.; Savontaus, E.

In: Journal of Neuroendocrinology, Vol. 25, No. 12, 12.2013, p. 1298-1307.

Research output: Contribution to journalArticle

Eerola, K, Nordlund, W, Virtanen, S, Dickens, AM, Mattila, M, Ruohonen, ST, Chua, Jr., SC, Wardlaw, SL, Savontaus, M & Savontaus, E 2013, 'Lentivirus-Mediated α-Melanocyte-Stimulating Hormone Overexpression in the Hypothalamus Decreases Diet Induced Obesity in Mice', Journal of Neuroendocrinology, vol. 25, no. 12, pp. 1298-1307. https://doi.org/10.1111/jne.12109
Eerola, K. ; Nordlund, W. ; Virtanen, S. ; Dickens, A. M. ; Mattila, M. ; Ruohonen, S. T. ; Chua, Jr., Streamson C. ; Wardlaw, S. L. ; Savontaus, M. ; Savontaus, E. / Lentivirus-Mediated α-Melanocyte-Stimulating Hormone Overexpression in the Hypothalamus Decreases Diet Induced Obesity in Mice. In: Journal of Neuroendocrinology. 2013 ; Vol. 25, No. 12. pp. 1298-1307.
@article{a9cae086df8f4821a434b81aff3a88f4,
title = "Lentivirus-Mediated α-Melanocyte-Stimulating Hormone Overexpression in the Hypothalamus Decreases Diet Induced Obesity in Mice",
abstract = "Melanocyte stimulating hormone (MSH) derived from the pro-hormone pro-opiomelanocortin (POMC) has potent effects on metabolism and feeding that lead to reduced body weight in the long-term. To determine the individual roles of POMC derived peptides and their sites of action, we created a method for the delivery of single MSH peptides using lentiviral vectors and studied the long-term anti-obesity effects of hypothalamic α-MSH overexpression in mice. An α-MSH lentivirus (LVi-α-MSH-EGFP) vector carrying the N'-terminal part of POMC and the α-MSH sequence was generated and shown to produce bioactive peptide in an in vitro melanin synthesis assay. Stereotaxis was used to deliver the LVi-α-MSH-EGFP or control LVi-EGFP vector to the arcuate nucleus (ARC) of the hypothalamus of male C57Bl/6N mice fed on a high-fat diet. The effects of 6-week-treatment on body weight, food intake, glucose tolerance and organ weights were determined. Additionally, a 14-day pairfeeding study was conducted to assess whether the weight decreasing effect of the LVi-α-MSH-EGFP treatment is dependent on decreased food intake. The 6-week LVi-α-MSH-EGFP treatment reduced weight gain (8.4 ± 0.4 g versus 12.3 ± 0.6 g; P < 0.05), which was statistically significant starting from 1 week after the injections. The weight of mesenteric fat was decreased and glucose tolerance was improved compared to LVi-EGFP treated mice. Food intake was decreased during the first week in the LVi-α-MSH-EGFP treated mice but subsequently increased to the level of LVi-EGFP treated mice. The LVi-EGFP injected control mice gained more weight even when pairfed to the level of food intake by LVi-α-MSH-EGFP treated mice. We demonstrate that gene transfer of α-MSH, a single peptide product of POMC, into the ARC of the hypothalamus, reduces obesity and improves glucose tolerance, and that factors other than decreased food intake also influence the weight decreasing effects of α-MSH overexpression in the ARC. Furthermore, viral MSH vectors delivered stereotaxically provide a novel tool for further exploration of chronic site-specific effects of POMC peptides.",
keywords = "α-MSH, Mice, Neuropeptides, Obesity, POMC",
author = "K. Eerola and W. Nordlund and S. Virtanen and Dickens, {A. M.} and M. Mattila and Ruohonen, {S. T.} and {Chua, Jr.}, {Streamson C.} and Wardlaw, {S. L.} and M. Savontaus and E. Savontaus",
year = "2013",
month = "12",
doi = "10.1111/jne.12109",
language = "English (US)",
volume = "25",
pages = "1298--1307",
journal = "Journal of Neuroendocrinology",
issn = "0953-8194",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Lentivirus-Mediated α-Melanocyte-Stimulating Hormone Overexpression in the Hypothalamus Decreases Diet Induced Obesity in Mice

AU - Eerola, K.

AU - Nordlund, W.

AU - Virtanen, S.

AU - Dickens, A. M.

AU - Mattila, M.

AU - Ruohonen, S. T.

AU - Chua, Jr., Streamson C.

AU - Wardlaw, S. L.

AU - Savontaus, M.

AU - Savontaus, E.

PY - 2013/12

Y1 - 2013/12

N2 - Melanocyte stimulating hormone (MSH) derived from the pro-hormone pro-opiomelanocortin (POMC) has potent effects on metabolism and feeding that lead to reduced body weight in the long-term. To determine the individual roles of POMC derived peptides and their sites of action, we created a method for the delivery of single MSH peptides using lentiviral vectors and studied the long-term anti-obesity effects of hypothalamic α-MSH overexpression in mice. An α-MSH lentivirus (LVi-α-MSH-EGFP) vector carrying the N'-terminal part of POMC and the α-MSH sequence was generated and shown to produce bioactive peptide in an in vitro melanin synthesis assay. Stereotaxis was used to deliver the LVi-α-MSH-EGFP or control LVi-EGFP vector to the arcuate nucleus (ARC) of the hypothalamus of male C57Bl/6N mice fed on a high-fat diet. The effects of 6-week-treatment on body weight, food intake, glucose tolerance and organ weights were determined. Additionally, a 14-day pairfeeding study was conducted to assess whether the weight decreasing effect of the LVi-α-MSH-EGFP treatment is dependent on decreased food intake. The 6-week LVi-α-MSH-EGFP treatment reduced weight gain (8.4 ± 0.4 g versus 12.3 ± 0.6 g; P < 0.05), which was statistically significant starting from 1 week after the injections. The weight of mesenteric fat was decreased and glucose tolerance was improved compared to LVi-EGFP treated mice. Food intake was decreased during the first week in the LVi-α-MSH-EGFP treated mice but subsequently increased to the level of LVi-EGFP treated mice. The LVi-EGFP injected control mice gained more weight even when pairfed to the level of food intake by LVi-α-MSH-EGFP treated mice. We demonstrate that gene transfer of α-MSH, a single peptide product of POMC, into the ARC of the hypothalamus, reduces obesity and improves glucose tolerance, and that factors other than decreased food intake also influence the weight decreasing effects of α-MSH overexpression in the ARC. Furthermore, viral MSH vectors delivered stereotaxically provide a novel tool for further exploration of chronic site-specific effects of POMC peptides.

AB - Melanocyte stimulating hormone (MSH) derived from the pro-hormone pro-opiomelanocortin (POMC) has potent effects on metabolism and feeding that lead to reduced body weight in the long-term. To determine the individual roles of POMC derived peptides and their sites of action, we created a method for the delivery of single MSH peptides using lentiviral vectors and studied the long-term anti-obesity effects of hypothalamic α-MSH overexpression in mice. An α-MSH lentivirus (LVi-α-MSH-EGFP) vector carrying the N'-terminal part of POMC and the α-MSH sequence was generated and shown to produce bioactive peptide in an in vitro melanin synthesis assay. Stereotaxis was used to deliver the LVi-α-MSH-EGFP or control LVi-EGFP vector to the arcuate nucleus (ARC) of the hypothalamus of male C57Bl/6N mice fed on a high-fat diet. The effects of 6-week-treatment on body weight, food intake, glucose tolerance and organ weights were determined. Additionally, a 14-day pairfeeding study was conducted to assess whether the weight decreasing effect of the LVi-α-MSH-EGFP treatment is dependent on decreased food intake. The 6-week LVi-α-MSH-EGFP treatment reduced weight gain (8.4 ± 0.4 g versus 12.3 ± 0.6 g; P < 0.05), which was statistically significant starting from 1 week after the injections. The weight of mesenteric fat was decreased and glucose tolerance was improved compared to LVi-EGFP treated mice. Food intake was decreased during the first week in the LVi-α-MSH-EGFP treated mice but subsequently increased to the level of LVi-EGFP treated mice. The LVi-EGFP injected control mice gained more weight even when pairfed to the level of food intake by LVi-α-MSH-EGFP treated mice. We demonstrate that gene transfer of α-MSH, a single peptide product of POMC, into the ARC of the hypothalamus, reduces obesity and improves glucose tolerance, and that factors other than decreased food intake also influence the weight decreasing effects of α-MSH overexpression in the ARC. Furthermore, viral MSH vectors delivered stereotaxically provide a novel tool for further exploration of chronic site-specific effects of POMC peptides.

KW - α-MSH

KW - Mice

KW - Neuropeptides

KW - Obesity

KW - POMC

UR - http://www.scopus.com/inward/record.url?scp=84888221624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888221624&partnerID=8YFLogxK

U2 - 10.1111/jne.12109

DO - 10.1111/jne.12109

M3 - Article

C2 - 24118213

AN - SCOPUS:84888221624

VL - 25

SP - 1298

EP - 1307

JO - Journal of Neuroendocrinology

JF - Journal of Neuroendocrinology

SN - 0953-8194

IS - 12

ER -